Member States Briefing – Allocation Round Results

February 25th 2021
WHO Emergency Use Listing (EUL) – review timelines

31st December: Pfizer/BioNTech

15th February: AZ/Serum Institute of India
AZ/SK Bio, Republic of Korea

End Feb: Moderna

March: Sinopharm BIBP
Sinovac
J&J*

In discussion: Gamaleya
Novavax

* Abridged procedure - EMA

https://extranet.who.int/pqweb/key-resources/documents/status-covid-19-vaccines-within-who-eulpq-evaluation-process
https://extranet.who.int/pqweb/sites/default/files/documents/Product-Eligibility_COVAX_Facility_Dec2020_0.pdf
Overview of the timeline and scope of the current allocation round

Allocation round scope
• Volumes in scope:
  – Jan-May volumes for SII and AZ

• Output of the allocation
  – Allocated volume per vaccine per participant for the whole round
    • AZ/SII doses from Jan (only India\(^1\)) to May
    • A pro-rated cap for Feb\(^1\)-March doses (proportional to the monthly supply for all participants) to allow for all ready participants to place POs aiming for March shipments

Key statistics
• 142 participants allocated
• Total allocated volume this round is 237M doses
• Overall weighted average coverage (all vaccines of this round): 2.46%

\(^1\) And voluntarily capped at 50M doses over the Feb-May period
Update on the AZ and SII allocation round - Overview of the supply

5% of the total Jan-May volume will be dedicated to the COVAX Buffer, but has been taken from the April-May volume.
Update on the AZ and SII allocation round - Overview of the allocations

Allocated population coverage, sorted by participant population proportion of population vaccinated, %

Minimum shipment sizes of:
- 2400 doses for AZ
- 12000 doses for SII

Higher coverage due to minimum allocation size of 100k doses (capped by requested coverage or pro-rata share)

Lower AZ coverage vs SII due to lower supply available

India capped at 50M doses

Pending supply availability confirmation

All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
Sequencing of delivery

- The Allocation will also include a stratified prioritization list for delivery sequence, ensuring balance between regions and income level, with the aim to have doses for all prepared participants by end of March.

- Based on that, shipments will be sequenced taking into account preparedness, logistics, flights and freight forwarders (see below for indicative process).

<table>
<thead>
<tr>
<th>Country preparedness</th>
<th>PO preparation</th>
<th>Manufacturing lead time</th>
<th>Shipment</th>
<th>In-country transportation</th>
</tr>
</thead>
<tbody>
<tr>
<td>• NDVP (assessed before allocation)</td>
<td>• Admin processing</td>
<td>• Packaging, Labeling</td>
<td>• Flights and Freight Forwarders</td>
<td>• Customs / import restrictions</td>
</tr>
<tr>
<td>• Regulatory approval/Import license</td>
<td>• Export preparation (for India only)</td>
<td>• Export authorizations</td>
<td>• Goods picked up and transported by freight forwarders</td>
<td>• Transfer of funds to manufacturers upon delivery</td>
</tr>
<tr>
<td>• I&amp;L agreements</td>
<td></td>
<td></td>
<td></td>
<td>• Transportation from port of entry to central warehouse to health center</td>
</tr>
<tr>
<td>• (for SFP) funds transferred to procurement agent</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Pending supply availability confirmation
Next steps

• **Friday Feb 25th (tbc)** - Detailed allocation outcomes will be shared with all participants (pending alignment with COVAX partners)

• Upon communication of the allocation outcomes, participants will be invited to place POs first for their Feb-March volumes, then for their April-May volumes

• **Monday Mar 1st** – COVAX Press event to release the results of the Allocation

• The next allocation round will be triggered upon EUL of a new vaccine in the COVAX portfolio with secured supply